Global Integrated Drug Discovery Service Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Integrated Drug Discovery Service Market Insights, Forecast to 2034
Integrated drug discovery service is a comprehensive approach to drug discovery that combines a variety of technologies and expertise to accelerate the process of developing new drugs. These services typically include
Target identification and validationThis involves identifying and validating the molecular targets of a disease.
Lead generationThis involves designing and synthesizing new molecules that have the potential to interact with the target molecule.
Lead optimizationThis involves improving the properties of lead molecules, such as their potency, selectivity, and safety.
Preclinical testingThis involves testing lead molecules in animal models to assess their efficacy and safety.
Clinical developmentThis involves testing lead molecules in human clinical trials to assess their safety and efficacy in humans.
Integrated drug discovery services can be provided by a variety of companies and organizations, including pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). These services can be tailored to the specific needs of each client, and they can help to reduce the time and cost of drug discovery.
Market Analysis and InsightsGlobal Integrated Drug Discovery Service Market
Global Integrated Drug Discovery Service market is expected to reach to US$ 21300 million in 2023, with a positive growth of %, compared with US$ 18300 million in 2022. Backed with the increasing demand from downstream industries, Integrated Drug Discovery Service industry is evaluated to reach US$ 46260 million in 2033. The CAGR will be 13.8% during 2023 to 2033.
The market is driven by the increasing demand for new drugs and therapies, as well as the advances in drug discovery technologies.
Here are some of the key trends that are driving the growth of the integrated drug discovery service market
Increasing demand for new drugs and therapiesThe aging population and the rising prevalence of chronic diseases are driving the demand for new drugs and therapies. According to the World Health Organization, chronic diseases account for 71% of all deaths worldwide. This is creating a significant demand for new drugs and therapies to treat these diseases.
Advances in drug discovery technologiesThere have been significant advances in drug discovery technologies in recent years. These advances have made it possible to discover and develop new drugs more quickly and efficiently. For example, the use of artificial intelligence (AI) and machine learning (ML) is now being used to identify new drug targets and to design new drugs.
Growing focus on personalized medicinePersonalized medicine is a field of medicine that aims to tailor treatments to the individual needs of patients. Integrated drug discovery services can be used to develop personalized drugs that are more effective and have fewer side effects.
Increased funding for researchGovernments and private organizations are investing heavily in research, including research in drug discovery. This is increasing the demand for integrated drug discovery services from pharmaceutical companies, biotechnology companies, and CROs.
The integrated drug discovery service market is a promising market with a lot of potential for growth. The market is driven by the increasing demand for new drugs and therapies, as well as the advances in drug discovery technologies. The key players in the market are investing heavily in research and development to develop new and innovative integrated drug discovery services.
Report Covers
This report presents an overview of global Integrated Drug Discovery Service market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Integrated Drug Discovery Service market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Syngene
Eurofins
Charles River
Evotec
BioAscent
Sygnature Discovery
Jubilant Biosys
Charnwood Molecular
Domainex
Pharmaron
Dalton Pharma Services
Selvita
Metrion Biosciences
WuXi AppTec
Malvern Panalytical
Hitgen
BioDuro
Curia Global
Taros Chemicals
Symeres
Aragen Life Sciences
Segment by Type
Ligand Based Drug Discovery
Structure Based Drug Discovery
Others
Biotech and Pharmaceutical Companies
Academic Institution
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Integrated Drug Discovery Service introduction, etc. Integrated Drug Discovery Service Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Integrated Drug Discovery Service
Chapter 13Methodology and Data Sources adopted by MRAResearch
Target identification and validationThis involves identifying and validating the molecular targets of a disease.
Lead generationThis involves designing and synthesizing new molecules that have the potential to interact with the target molecule.
Lead optimizationThis involves improving the properties of lead molecules, such as their potency, selectivity, and safety.
Preclinical testingThis involves testing lead molecules in animal models to assess their efficacy and safety.
Clinical developmentThis involves testing lead molecules in human clinical trials to assess their safety and efficacy in humans.
Integrated drug discovery services can be provided by a variety of companies and organizations, including pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). These services can be tailored to the specific needs of each client, and they can help to reduce the time and cost of drug discovery.
Market Analysis and InsightsGlobal Integrated Drug Discovery Service Market
Global Integrated Drug Discovery Service market is expected to reach to US$ 21300 million in 2023, with a positive growth of %, compared with US$ 18300 million in 2022. Backed with the increasing demand from downstream industries, Integrated Drug Discovery Service industry is evaluated to reach US$ 46260 million in 2033. The CAGR will be 13.8% during 2023 to 2033.
The market is driven by the increasing demand for new drugs and therapies, as well as the advances in drug discovery technologies.
Here are some of the key trends that are driving the growth of the integrated drug discovery service market
Increasing demand for new drugs and therapiesThe aging population and the rising prevalence of chronic diseases are driving the demand for new drugs and therapies. According to the World Health Organization, chronic diseases account for 71% of all deaths worldwide. This is creating a significant demand for new drugs and therapies to treat these diseases.
Advances in drug discovery technologiesThere have been significant advances in drug discovery technologies in recent years. These advances have made it possible to discover and develop new drugs more quickly and efficiently. For example, the use of artificial intelligence (AI) and machine learning (ML) is now being used to identify new drug targets and to design new drugs.
Growing focus on personalized medicinePersonalized medicine is a field of medicine that aims to tailor treatments to the individual needs of patients. Integrated drug discovery services can be used to develop personalized drugs that are more effective and have fewer side effects.
Increased funding for researchGovernments and private organizations are investing heavily in research, including research in drug discovery. This is increasing the demand for integrated drug discovery services from pharmaceutical companies, biotechnology companies, and CROs.
The integrated drug discovery service market is a promising market with a lot of potential for growth. The market is driven by the increasing demand for new drugs and therapies, as well as the advances in drug discovery technologies. The key players in the market are investing heavily in research and development to develop new and innovative integrated drug discovery services.
Report Covers
This report presents an overview of global Integrated Drug Discovery Service market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Integrated Drug Discovery Service market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Syngene
Eurofins
Charles River
Evotec
BioAscent
Sygnature Discovery
Jubilant Biosys
Charnwood Molecular
Domainex
Pharmaron
Dalton Pharma Services
Selvita
Metrion Biosciences
WuXi AppTec
Malvern Panalytical
Hitgen
BioDuro
Curia Global
Taros Chemicals
Symeres
Aragen Life Sciences
Segment by Type
Ligand Based Drug Discovery
Structure Based Drug Discovery
Others
Segment by Application
Biotech and Pharmaceutical Companies
Academic Institution
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Integrated Drug Discovery Service introduction, etc. Integrated Drug Discovery Service Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Integrated Drug Discovery Service
Chapter 13Methodology and Data Sources adopted by MRAResearch